The three deep intronic GLA mutations with prominent clinical heterogeneity highlight the contribution of aberrant splicing of GLA transcripts to FD and also implies that approaches to restore normal splicing of GLA transcripts may benefit patients carrying deep intronic GLA mutations. This evidence concerns the gene GLA and Fabry disease.